Dupilumab is in development for the treatment of children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) uncontrolled with currently available therapies. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Dupilumab acts by blocking certain proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13) and mediating the pathways involved in the inflammatory process in AD. Dupilumab is taken subcutaneously (SC) and is currently licensed for the treatment of moderate to severe AD in adults who are candidates for systemic therapy. If licensed, dupilumab will offer an additional treatment option for children aged ≥ 6 to < 12 years with severe AD.
Secukinumab as a subcutaneous injection is in clinical development for the treatment of enthesitis related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions belong to a group of arthritis conditions of unknown cause known as juvenile idiopathic arthritis which affect children. JPsA patients have arthritis and psoriasis, an inflammatory skin disease and ERA patients have arthritis and enthesitis, inflammation of the ligaments and tendons. These conditions are the result of the immune system mistakenly attacking the body’s own cells at the joints and the skin or tendons, causing swelling, pain and reduced mobility.